STOCK TITAN
  1. Home
  2. Sec-filings
  3. LENZ
  4. [Form 4] LENZ Therapeutics, Inc. Insider Trading Activity

LENZ Therapeutics (LENZ) grants stock options and RSUs to CMO Marc Odrich

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. reported an equity grant to its Chief Medical Officer, Marc Odrich, effective January 2, 2026. He received a stock option for 84,200 shares of common stock with an exercise price of $16 per share, expiring on January 1, 2036. The option vests 25% one year after the January 2, 2026 vesting commencement date, with the remaining shares vesting monthly over three years, contingent on his continued service under the company’s 2024 Equity Incentive Plan.

Odrich also received 14,000 restricted stock units (RSUs), each representing one share of common stock. For this award, 25% of the RSUs vest one year after the January 2, 2026 grant date, with the remaining RSUs vesting in eight equal installments every six months, also subject to continued service. Both the options and RSUs are reported as directly owned following these grants.

Positive

  • None.

Negative

  • None.
Insider Odrich Marc
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 84,200 $0.00 --
Grant/Award Restricted Stock Unit 14,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 84,200 shares (Direct); Restricted Stock Unit — 14,000 shares (Direct)
Footnotes (1)
  1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Odrich Marc
(Last) (First) (Middle)
C/O LENZ THERAPEUTICS, INC.
201 LOMAS SANTA FE DRIVE, SUITE 300
(Street)
SOLANA BEACH CA 92075
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $16 01/02/2026 A 84,200 (1) 01/01/2036 Common Stock 84,200 $0 84,200 D
Restricted Stock Unit (2) 01/02/2026 A 14,000 (3) (3) Common Stock 14,000 $0 14,000 D
Explanation of Responses:
1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.
Remarks:
/s/ Daniel R. Chevallard, as Attorney-in-Fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did LENZ (LENZ) report for Marc Odrich?

LENZ Therapeutics reported that Chief Medical Officer Marc Odrich received a grant of 84,200 stock options and 14,000 restricted stock units on January 2, 2026, all held as direct ownership.

What are the terms of Marc Odrich’s stock option grant at LENZ (LENZ)?

Odrich’s stock option covers 84,200 shares of common stock at an exercise price of $16 per share, expiring on January 1, 2036. It vests 25% one year after January 2, 2026, with the remaining shares vesting monthly over three years, subject to continued service.

How do the RSUs granted to LENZ CMO Marc Odrich vest?

The 14,000 RSUs granted on January 2, 2026 vest 25% on the one-year anniversary of that date. The remaining RSUs vest in eight equal installments every six months thereafter, conditioned on Odrich remaining a service provider.

What does each RSU granted to Marc Odrich by LENZ represent?

Each restricted stock unit (RSU) represents a contingent right to receive one share of LENZ Therapeutics’ common stock, delivered as the units vest.

Is Marc Odrich’s ownership in LENZ reported as direct or indirect?

The Form 4 shows both the 84,200 stock options and 14,000 RSUs as direct (D) ownership by Marc Odrich, with no separate entity listed for indirect ownership.

What service condition applies to Marc Odrich’s LENZ equity awards?

Both the stock options and RSUs vest only if Odrich continues to be a Service Provider under LENZ’s 2024 Equity Incentive Plan through each applicable vesting date.